SXI Life Sciences
7.474,53
PKT
-41,24
PKT
-0,55
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
22.10.15 | Novartis Outperform | BNP PARIBAS | |
21.10.15 | Roche Outperform | Bernstein Research | |
21.10.15 | Novartis Outperform | Bernstein Research | |
21.10.15 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
21.10.15 | Novartis Neutral | Goldman Sachs Group Inc. | |
20.10.15 | Roche buy | UBS AG | |
16.10.15 | Roche overweight | JP Morgan Chase & Co. | |
16.10.15 | Novartis overweight | JP Morgan Chase & Co. | |
15.10.15 | Roche buy | UBS AG | |
12.10.15 | Roche overweight | JP Morgan Chase & Co. | |
12.10.15 | Novartis buy | Jefferies & Company Inc. | |
12.10.15 | Roche buy | Jefferies & Company Inc. | |
09.10.15 | Roche Neutral | Citigroup Corp. | |
09.10.15 | Roche overweight | Morgan Stanley | |
09.10.15 | Roche overweight | JP Morgan Chase & Co. | |
06.10.15 | Roche overweight | JP Morgan Chase & Co. | |
01.10.15 | Roche buy | HSBC | |
30.09.15 | Roche overweight | JP Morgan Chase & Co. | |
30.09.15 | Roche buy | HSBC | |
29.09.15 | Roche overweight | JP Morgan Chase & Co. | |
29.09.15 | Roche Outperform | BNP PARIBAS | |
28.09.15 | Roche buy | Kepler Cheuvreux | |
28.09.15 | Roche verkaufen | Goldman Sachs Group Inc. | |
25.09.15 | Novartis overweight | JP Morgan Chase & Co. | |
25.09.15 | Roche buy | Deutsche Bank AG | |
23.09.15 | Novartis buy | Citigroup Corp. | |
16.09.15 | Novartis buy | HSBC | |
15.09.15 | Roche buy | Goldman Sachs Group Inc. | |
10.09.15 | Roche buy | Jefferies & Company Inc. | |
10.09.15 | Novartis buy | Jefferies & Company Inc. | |
03.09.15 | Novartis Halten | Independent Research GmbH | |
01.09.15 | Novartis buy | UBS AG | |
24.08.15 | Novartis buy | UBS AG | |
21.08.15 | Roche buy | UBS AG | |
13.08.15 | Roche buy | HSBC | |
07.08.15 | Novartis buy | Jefferies & Company Inc. | |
07.08.15 | Roche buy | Jefferies & Company Inc. | |
29.07.15 | Roche buy | UBS AG | |
29.07.15 | Roche overweight | JP Morgan Chase & Co. | |
28.07.15 | Roche overweight | Barclays Capital |